Market news

Pacira Biosciences (PCRX) has an average rating of overweight and mean price target of $30, accordin

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Motley Fool Press Release.

Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

Pacira BioSciences (PCRX) outlook: EXPAREL reimbursement tailwinds, iovera° divestiture, pipeline catalysts, and valuation discount. Read the bull case here.

Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

— A single locally administered intra-articular injection of PCRX-201 into the knee was well tolerated in patients with moderate-to-severe knee osteoarthritis — — Exploratory clinical outcome measures showed improvements out to two years in pain, stiffness, and function across all doses and groups — — Phase 2 ASCEND trial of PCRX-201 in knee osteoarthritis advancing with first topline read out on track for year-end 2026 — BRISBANE, Calif., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, In

Detailed price information for Pacira Pharm Inc (PCRX-Q) from The Globe and Mail including charting and trades.

PCRX beats Q2 earnings estimates as higher product sales boost revenues, with Exparel demand and portfolio momentum supporting growth despite a guidance cut.

Pacira BioSciences Inc (PCRX) reports a 6% revenue increase, advances EXPAREL reimbursement, and completes iovera divestiture to sharpen focus on core pipeline.

Pacira BioSciences (NASDAQ:PCRX) reported second-quarter 2026 revenue growth, led by higher sales of its EXPAREL, ZILRETTA and iovera° products, while highlighting expanded payer coverage, pipeline progress and the completed sale of iovera° to Zimmer Biomet. Total second-quarter revenue rose 6% fro

Pacira (PCRX) delivered earnings and revenue surprises of +14.06% and +1.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

-- Continued execution of 5x30 strategy marked by solid revenue growth, durable cashflows, advancing pipeline, and high-caliber commercial partnerships -- -- Delivered second quarter total revenue of $192.4 million, representing 6 percent year-over-year growth -- -- Conference call today at 4:30 p.m. ET -- BRISBANE, Calif., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform

- Survey findings highlight the prevalence of knee pain, reported impacts on work and quality of life, and strong interest in long-lasting, non-opioid treatment options - BRISBANE, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced findings from the Standing Strong: The Impact of Pain on America's Workforce survey, which explor

— First patient enrolled in Part B of Phase 2 ASCEND study enabled by availability of drug product from new manufacturing process —— Topline data from Part A of Phase 2 ASCEND study remains on track for end of year — BRISBANE, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (NASDAQ: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it has successfully transitioned PCRX-201 (ene

Pacira BioSciences (PCRX) said Monday that it has enrolled the first patient in part B of its mid-st

BRISBANE, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will report its second quarter 2026 financial results after the close of the U.S. markets on Tuesday August 4, 2026. Following the release, the company will host a live conference call and webcast at 4:30 p.m. ET. For listeners who wish to participate in the q